Literature DB >> 12019188

Imipramine N-glucuronidation in human liver microsomes: biphasic kinetics and characterization of UDP-glucuronosyltransferase isoforms.

Miki Nakajima1, Eriko Tanaka, Tomo Kobayashi, Noriko Ohashi, Toshiyuki Kume, Tsuyoshi Yokoi.   

Abstract

A method for the direct determination of imipramine N-glucuronidation in human liver microsomes by high-performance liquid chromatography with UV detection was developed. Imipramine was incubated with human liver microsomes and UDP-glucuronic acid. The Eadie-Hofstee plots of imipramine N-glucuronidation in human liver microsomes were biphasic. For the high-affinity component, the K(m) was 97.2 +/- 39.4 microM and the V(max) was 0.29 +/- 0.03 nmol/min/mg of protein. For the low-affinity component, the K(m) was 0.70 +/- 0.29 mM and the V(max) was 0.90 +/- 0.28 nmol/min/mg of protein. The imipramine N-glucuronosyltransferase activities were not detectable in two samples of human jejunum microsomes. Among recombinant UDP-glucuronosyltransferases (UGTs) in baculovirus-infected insect cells (Supersomes or Bacurosomes) or human B-lymphoblastoid cells tested in the present study (UGT1A1, UGT1A3, UGT1A4, UGT1A6, UGT1A7, UGT1A8, UGT1A9, UGT1A10, UGT2B7, and UGT2B15), only UGT1A4 showed imipramine N-glucuronosyltransferase activity. The activity in UGT1A4 Supersomes was higher than that in recombinant UGT1A4 expressed in human B-lymphoblastoid cells at all imipramine concentration tested. The kinetics of imipramine N-glucuronidation in UGT1A4 Supersomes did not fit the Michaelis-Menten plot, showing a K(m) of >1 mM. In contrast, in UGT1A4 expressed in human B-lymphoblastoid cells, K(m) was 0.71 +/- 0.36 mM and the V(max) was 0.11 +/- 0.03 nmol/min/mg of protein. Interindividual differences in the imipramine N-glucuronidation in liver microsomes from 14 humans were at most 2.5-fold. The imipramine N-glucuronosyltransferase activities in 11 human liver microsomes were significantly (r = 0.817, P < 0.005) correlated with the glucuronosyltransferase activities of trifluoperazine, a typical substrate of UGT1A4. This is the first report of the biphasic kinetics of imipramine N-glucuronide in human liver microsomes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12019188     DOI: 10.1124/dmd.30.6.636

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  10 in total

1.  Glucuronidation of OTS167 in Humans Is Catalyzed by UDP-Glucuronosyltransferases UGT1A1, UGT1A3, UGT1A8, and UGT1A10.

Authors:  Jacqueline Ramírez; Snezana Mirkov; Larry K House; Mark J Ratain
Journal:  Drug Metab Dispos       Date:  2015-04-13       Impact factor: 3.922

2.  In vitro glucuronidation of aprepitant: a moderate inhibitor of UGT2B7.

Authors:  Larry House; Jacqueline Ramirez; Michael Seminerio; Snezana Mirkov; Mark J Ratain
Journal:  Xenobiotica       Date:  2015-06-08       Impact factor: 1.908

3.  Heterologous expression of active human uridine diphosphate glucuronosyltransferase 1A3 in Chinese hamster lung cells.

Authors:  Ya-Kun Chen; Xin Li; Shu-Qing Chen; Su Zeng
Journal:  World J Gastroenterol       Date:  2005-01-07       Impact factor: 5.742

4.  Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.

Authors:  Shu-Feng Zhou
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

5.  Identification of human UDP-glucuronosyltransferases catalyzing hepatic 1alpha,25-dihydroxyvitamin D3 conjugation.

Authors:  Takanori Hashizume; Yang Xu; Michael A Mohutsky; Jeffrey Alberts; Chad Hadden; Thomas F Kalhorn; Nina Isoherranen; Margaret C Shuhart; Kenneth E Thummel
Journal:  Biochem Pharmacol       Date:  2007-11-22       Impact factor: 5.858

6.  Comparison of the drug-drug interactions potential of erlotinib and gefitinib via inhibition of UDP-glucuronosyltransferases.

Authors:  Yong Liu; Jacqueline Ramírez; Larry House; Mark J Ratain
Journal:  Drug Metab Dispos       Date:  2010-01       Impact factor: 3.922

7.  Genetic factors affecting gene transcription and catalytic activity of UDP-glucuronosyltransferases in human liver.

Authors:  Wanqing Liu; Jacqueline Ramírez; Eric R Gamazon; Snezana Mirkov; Peixian Chen; Kehua Wu; Chang Sun; Nancy J Cox; Edwin Cook; Soma Das; Mark J Ratain
Journal:  Hum Mol Genet       Date:  2014-05-30       Impact factor: 6.150

Review 8.  Species differences in drug glucuronidation: Humanized UDP-glucuronosyltransferase 1 mice and their application for predicting drug glucuronidation and drug-induced toxicity in humans.

Authors:  Ryoichi Fujiwara; Emiko Yoda; Robert H Tukey
Journal:  Drug Metab Pharmacokinet       Date:  2017-10-07       Impact factor: 3.614

9.  Characterization of tamoxifen and 4-hydroxytamoxifen glucuronidation by human UGT1A4 variants.

Authors:  Dongxiao Sun; Gang Chen; Ryan W Dellinger; Kimberly Duncan; Jia-Long Fang; Philip Lazarus
Journal:  Breast Cancer Res       Date:  2006       Impact factor: 6.466

10.  Glucuronidation of drugs in humanized UDP-glucuronosyltransferase 1 mice: Similarity with glucuronidation in human liver microsomes.

Authors:  Yuki Kutsuno; Kyohei Sumida; Tomoo Itoh; Robert H Tukey; Ryoichi Fujiwara
Journal:  Pharmacol Res Perspect       Date:  2013-09-03
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.